Keyphrases
Childhood Acute Lymphoblastic Leukemia
100%
Direct Therapy
100%
Multicenter Trial
100%
Minimal Residual Disease
100%
High Dose
44%
Clinical High Risk
33%
Hematopoietic Stem Cell Transplantation
33%
Overall Survival
22%
Improved Outcomes
22%
Genetic Abnormalities
22%
Mixed-phenotype Acute Leukemia
22%
Acute Myeloid Leukemia
22%
Etoposide
22%
Standard Risk
22%
Chemotherapy
22%
Monoclonal Antibody
11%
High Risk
11%
Cumulative Incidence
11%
Leukemia
11%
Event-free Survival
11%
Hazard Ratio
11%
Morphological Variation
11%
Risk-adapted Therapy
11%
Low-dose Cytarabine
11%
Unrelated Donor
11%
Working Diagnosis
11%
Annualized Relapse Rate
11%
Flow Cytometry
11%
Stratification Strategy
11%
Risk Classification
11%
Toxic Effects
11%
Consolidation Therapy
11%
Genetic Features
11%
Risk Stratification
11%
National Institutes of Health
11%
Gemtuzumab Ozogamicin
11%
Low-risk Patients
11%
Syrian
11%
Leukaemic Cells
11%
Adverse Prognostic Factor
11%
Accruals
11%
Cytarabine
11%
Induction Failure
11%
Daunorubicin
11%
SE(3)
11%
CD33
11%
Feature Residual
11%
Comprehensive Risk
11%
Myelodysplasia
11%
De Novo Acute Myeloid Leukemia
11%
Targeted Chemotherapy
11%
Complete Remission
11%
Therapy-related
11%
Medicine and Dentistry
Minimal Residual Disease
100%
Acute Myeloid Leukemia
100%
Drug Megadose
44%
Low Drug Dose
44%
Hematopoietic Stem Cell Transplantation
33%
Leukemia
33%
Chemotherapy
33%
Cumulative Incidence
22%
Cytarabine
22%
Event Free Survival
22%
Etoposide
22%
Overall Survival
22%
Gemtuzumab Ozogamicin
11%
Flow Cytometry
11%
Myelodysplastic Syndrome
11%
Toxicity
11%
Liposomal Daunorubicin
11%
Risk Stratification
11%
Hazard Ratio
11%
Morphology
11%
Monoclonal Antibody
11%
Prognostic Factor
11%
De Novo Acute Myeloid Leukemia
11%
Infection
11%